%PDF-1.5
%
25 0 obj
<>
endobj
678 0 obj
<>stream
QuarkXPress(tm) 6.5
%%DocumentProcessColors: Black
%%EndComments
2005-08-05T16:22:19Z
QuarkXPress(tm) 6.5
2024-03-28T11:00:38-07:00
2024-03-28T11:00:38-07:00
uuid:0f6714bb-081b-11da-831a-0003936da214
uuid:819a6276-1dd2-11b2-0a00-bf00389da5ff
application/pdf
2004-568.sept
endstream
endobj
20 0 obj
<>]>>
endobj
21 0 obj
<>
endobj
27 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
3 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
704 0 obj
[710 0 R]
endobj
705 0 obj
<>stream
1 g
/GS0 gs
0 783 0 0 re
f
0 0 0 1 K
/GS1 gs
40.464 72 m
545.472 72 l
S
0 0 0 0 k
39.322 49.4999 64.178 15.665 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
8 0 0 8 40.3216 52.2343 Tm
(1836)Tj
ET
0 0 0 0 k
342.5 49.4999 203 15.665 re
f
BT
0 0 0 1 k
/T1_0 1 Tf
0.02499 Tw 8 0 0 8 410.8613 52.2343 Tm
(The Journal of Rheumatology 2005; 32:9)Tj
ET
0 0 0 0 k
/GS2 gs
91.131 66.9169 407.5 10.833 re
f
0.5 w
/GS1 gs
91.131 66.9169 407.5 10.833 re
h
S
BT
0 0 0 1 k
/T1_1 1 Tf
0.035 Tw 10 0 0 10 39.968 731.1616 Tm
[(lar folate to a greater extent in the tar)20 (get tissue with respect)]TJ
-0.00011 Tc 0 -1.2 TD
(to)Tj
0 Tc 0.17799 Tw 1.2053 0 Td
(immunosuppression or inflammation, without lowering)Tj
0.008 Tw -1.2054 -1.2 Td
[(systemic folate concentrations \(i.e., no association with tox)2 (-)]TJ
0.22301 Tw T*
[(icity\). Because the 1298C SNP)-436 (alone is not consistently)]TJ
0.004 Tw T*
(associated with decreased plasma folate levels, but has been)Tj
0.00999 Tw T*
(associated with lower MTHFR activity in lymphocytes, it is)Tj
T*
(p)Tj
0.01401 Tw (lausible that these patients have better disease control with)Tj
0.026 Tw T*
(lower toxicity)Tj
0 Tw 7.5 0 0 7.5 96.0394 650.4615 Tm
(18)Tj
10 0 0 10 103.5394 647.1616 Tm
(.)Tj
0.026 Tw 0.5078 0 Td
[(This may explain why therapeutic ef)19 (ficacy)]TJ
0.01801 Tw -6.8649 -1.2 Td
(of MTX in patients with the 1298C allele has been found to)Tj
0.02499 Tw T*
[(exceed the ef)19 (ficacy in those without the allele.)]TJ
0.27699 Tw 1.2 -1.2 Td
(Polymorphisms within the MTHFR gene seem to be)Tj
0.03101 Tw -1.2 -1.2 Td
[(associated with both the ef)19 (ficacy and toxicity of methotrex)2 (-)]TJ
0.07001 Tw T*
[(ate by both single locuses. It may be speculated that deter)3 (-)]TJ
0.063 Tw T*
[(mination of the MTHFR genotype would be clinically use)2 (-)]TJ
0.05 Tw T*
[(ful when JIA)-246 (patients are treated with MTX to estimate the)]TJ
0.071 Tw T*
(risk of developing adverse events and the risk of treatment)Tj
-0.015 Tw T*
[(failure. However)40 (, these results are preliminary and will need)]TJ
0.19099 Tw T*
(confirmation by further observation, since the number of)Tj
0.147 Tw T*
[(patients with the 677T)-378 (allele in our study population was)]TJ
0 Tw T*
[(low)65 (.)]TJ
/T1_2 1 Tf
-0.00004 -2.4 Td
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 46.968 469.1616 Tm
[(1.)-875 (Minden K, Niewerth M, Listing J, Zink )55 (A; German Study Group of)]TJ
1.675 -1.25 Td
(Pediatric Rheumatologists. Health care provision in pediatric)Tj
0 -1.25 TD
(rheumatology in Germany \321 national rheumatologic database. )Tj
T*
[(J)-274.9 (Rheumatol 2002;29:622-8.)]TJ
0 Tw -1.675 -1.25 Td
(2.)Tj
0.02499 Tw 1.625 0 Td
[(Ramanan )55 (A)129 (V)129 (, )18 (Whitworth P)111 (, Baildam EM. Use of methotrexate in)]TJ
0.05 -1.25 Td
[(juvenile idiopathic arthritis. )57 (Arch Dis Child 2003;88:197-200.)]TJ
-1.675 -1.25 Td
[(3.)-875 (Chan ES, Cronstein BN. Molecular action of methotrexate in)]TJ
1.675 -1.25 Td
[(inflammatory diseases. )56 (Arthritis Res 2002;4:266-73. E-pub 2002)]TJ
T*
(March 19.)Tj
-1.675 -1.25 Td
[(4.)-875 (Cronstein BN, Montesinos MC, Chan ES. )54 (Adenosine mediates the)]TJ
1.675 -1.25 Td
[(anti-inflammatory ef)19 (fects of methotrexate as well as its toxicities.)]TJ
T*
(Drug Dev Res 2001;52:394-6.)Tj
0 Tw -1.675 -1.25 Td
(5.)Tj
0.02499 Tw 1.625 0 Td
(Rozen R. Molecular genetics of methylenetetrahydrofolate )Tj
0.05 -1.25 Td
[(reductase deficiency)66 (. J Inherit Metab Dis 1996;19:589-94.)]TJ
0 Tw -1.675 -1.25 Td
(6.)Tj
0.02499 Tw 1.625 0 Td
(Ranganathan P)Tj
-0.00011 Tc 5.9403 0 Td
(,)Tj
0 Tc 0.5249 0 Td
[(Eisen S, )37.4 (Y)]TJ
0 Tw 4.1627 0 Td
(okoyama )Tj
0.02499 Tw 3.9227 0 Td
(WM, McLeod HL. )Tj
0 Tw 7.8602 0 Td
[(W)40 (ill )]TJ
0.02499 Tw -22.3607 -1.25 Td
(pharmacogenetics allow better prediction of methotrexate toxicity)Tj
T*
[(and ef)18.4 (ficacy in patients with rheumatoid arthritis? )57 (Ann Rheum Dis)]TJ
0 Tw T*
(2003;62:4-9.)Tj
0.02499 Tw -1.675 -1.25 Td
[(7.)-875 (V)111 (an der Put NM, Gabreels F)79 (, Stevens EM, et al. )56 (A)-220 (second common)]TJ
1.675 -1.25 Td
(mutation in the methylenetetrahydrofolate reductase gene: an )Tj
T*
[(additional risk factor for neural-tube defects? )57 (Am J Hum Genet)]TJ
0 Tw T*
(1998;62:1044-51.)Tj
0.02499 Tw 31.3875 59.171 Td
[(8.)-875 (W)80 (eisber)18 (g I, )18 (T)35 (ran P)110 (, Christensen B, Sibani S, Rozen R. )55 (A)-220 (second)]TJ
1.675 -1.25 Td
(genetic polymorphism in methylenetetrahydrofolate reductase)Tj
-0.00011 Tc T*
(\()Tj
0 Tc [(MTHFR\) associated with decreased enzyme activity)67 (. Mol Genet)]TJ
T*
(Metab 1998;64:169-72.)Tj
-1.675 -1.25 Td
[(9.)-875 (Petty RE, Southwood )18 (TR, Manners P)110 (, et al. International League of)]TJ
1.675 -1.25 Td
(Associations for Rheumatology classification of juvenile idiopathic)Tj
T*
(arthritis: second revision, Edmonton, 2001. J Rheumatol)Tj
0 Tw T*
(2004;31:390-2.)Tj
0.02499 Tw -2.175 -1.25 Td
[(10.)-875 (Frosst P)110 (, Blom HJ, Milos R, et al. )55 (A)-220 (candidate genetic risk )]TJ
2.175 -1.25 Td
(factor for vascular disease: a common mutation in )Tj
T*
[(methylenetetrahydrofolate reductase. Nature Genet 1995;10:1)40 (1)37 (1-3.)]TJ
-2.1381 -1.25 Td
[(1)37 (1.)-875 (Hanson NQ, )54 (Aras O, )36 (Y)100 (ang F)80 (, )18 (T)69 (sai MY)129 (. C677T)-257 (and )55 (A1298C )]TJ
2.1381 -1.25 Td
(polymorphisms of the methylenetetrahydrofolate reductase gene:)Tj
T*
[(incidence and ef)19 (fect of combined genotypes on plasma fasting and)]TJ
T*
(post-methionine load homocysteine in vascular disease. Clin Chem)Tj
0 Tw T*
(2001;47:661-6.)Tj
0.02499 Tw -2.175 -1.25 Td
[(12.)-875 (Haagsma CJ, Blom HJ, van Riel PL, et al. Influence of )]TJ
2.175 -1.25 Td
(sulphasalazine, methotrexate, and the combination of both on )Tj
T*
(plasma homocysteine concentrations in patients with rheumatoid)Tj
T*
[(arthritis. )55 (Ann Rheum Dis 1999;58:79-84.)]TJ
-2.175 -1.25 Td
[(13.)-875 (Andersen LS, Hansen EL, Knudsen JB, )17 (W)80 (ester JU, Hansen GV)128 (,)]TJ
2.175 -1.25 Td
[(Hansen )18 (TM. Prospectively measured red cell folate levels in)]TJ
T*
(methotrexate treated patients with rheumatoid arthritis: relation to)Tj
T*
[(withdrawal and side ef)18 (fects. J Rheumatol 1997;24:830-7.)]TJ
-2.175 -1.25 Td
[(14.)-875 (V)111 (an Ede )55 (AE, Laan RF)80 (, Blom HJ, et al. Homocysteine and folate sta)1 (-)]TJ
2.175 -1.25 Td
(tus in methotrexate-treated patients with rheumatoid arthritis.)Tj
T*
(Rheumatology Oxford 2002;41:658-65.)Tj
-2.175 -1.25 Td
[(15.)-875 (V)111 (an Ede )55 (AE, Laan RF)80 (, Blom HJ, et al. )18 (The C677T)-257 (mutation in the)]TJ
2.175 -1.25 Td
(methylenetetrahydrofolate reductase gene: a genetic risk factor for)Tj
T*
(methotrexate-related elevation of liver enzymes in rheumatoid)Tj
T*
[(arthritis patients. )56 (Arthritis Rheum 2001;44:2525-30.)]TJ
-2.175 -1.25 Td
[(16.)-875 (Kumagai K, Hiyama K, Oyama )18 (T)74 (, Maeda H, Kohno N.)]TJ
2.175 -1.25 Td
(Polymorphisms in the thymidylate synthase and )Tj
T*
(methylenetetrahydrofolate reductase genes and sensitivity to the)Tj
T*
(low-dose methotrexate therapy in patients with rheumatoid arthritis.)Tj
T*
(Int J Mol Med 2003;1)Tj
0 Tw 8.84 0 Td
(1:593-600.)Tj
0.02499 Tw -11.015 -1.25 Td
[(17.)-875 (Urano )18 (W)91 (, )18 (T)70 (aniguchi )56 (A, )36 (Y)100 (amanaka H, et al. Polymorphisms in the)]TJ
2.175 -1.25 Td
(methylenetetrahydrofolate reductase gene were associated with both)Tj
T*
[(the ef)18.5 (ficacy and the toxicity of methotrexate used for the )]TJ
T*
(treatment of rheumatoid arthritis, as evidenced by single locus and)Tj
T*
(haplotype analyses. Pharmacogenetics 2002;12:183-90.)Tj
0 Tw -2.175 -1.25 Td
[(18.)-875 (Evans )]TJ
0.02499 Tw 4.8258 0 Td
[(WE. Dif)18.6 (fering ef)19 (fects of methylenetetrahydrofolate reductase)]TJ
-2.6508 -1.25 Td
[(single nucleotide polymorphisms on methotrexate ef)20 (ficacy and )]TJ
T*
(toxicity in rheumatoid arthritis. Pharmacogenetics 2002;12:181-2.)Tj
ET
q
1 0 0 1 0 -5 cm
0 0 585 783 re
W n
1 0 0 1 0 5 cm
BT
0 g
ET
/GS3 gs
BT
/T1_3 8 Tf
0 Tw 95.328 69 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS4 gs
/T1_4 1 Tf
0 Tw 10 0 0 10 513 8 Tm
( )Tj
0 0.48627 0.77255 rg
/GS4 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS4 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
29 0 obj
<>
endobj
30 0 obj
<>
endobj
18 0 obj
<>
endobj
57 0 obj
<>
endobj
685 0 obj
<>
endobj
15 0 obj
<>
endobj
16 0 obj
<>
endobj
17 0 obj
<>stream
Xe]T'@lYAVb<5#1]d0
b)XQ&jDոh)Z-9sl4=ٽ˞9=w{(y%N_b8}z=>VjdU y9~&Va477I-G+l-Mљu'mZYYEa[_Vᰔk[MSLvQ̢MHW`N,V8mV'hlV6ܲbD<6{uie1xS,FS*NMxjuCMdjK
E퓅Ȗr~"_+{PgQ?jjo;`k[05|̭0v7u7@&q5Fܭ803xR|sSz5\rn_;M/֛M
^@_H*]0ϐXE1#Z,Y_dE|{CqpKOG_ˑξaBƍcZZ#[57+3aNɤ87Pvq}(`|+Llhrh`-_ .%μ|F`c
Ў[60_Cpц|'xb<|dyvwEJloDg=#VJV/<@뜓;UF=\h
%7Kn(euݬIZMf:I3PP$0m?!6Sݒ]lXX'~s~g'awHA獮=YpʽTμTtKmǏ` p54ł\pkmU8^Xzu!u@xmg.s+De['^
7|&1 N4IrMG}%7g`wJc 0gJ߫_a%20WƢ"Q8YZP }=*[ OBA1 :Q)fb(@{UÌgڞ5'W*9֢Xq7h:t >L2g{8c͘*G&mFgK`RW?q'fGYn^;8{jw$EQWZ3&!T:{|)v=Uy,,f1J{rl饌fxNS`BSXP>$)Aw ƝxAW?@
ݗI^3Ox.c fC-yY.3D[sPÉAV:T`w 2 xA&(dd 58TaXhXb|d&(ꎻ8O`